Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 (mut) measurable residual disease (MRD) using off‐label venetoclax in combination with low‐dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, includi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Tiong, Ing S., Dillon, Richard, Ivey, Adam, Teh, Tse‐Chieh, Nguyen, Phillip, Cummings, Nicholas, Taussig, David C., Latif, Annie‐Louise, Potter, Nicola E., Runglall, Manohursingh, Russell, Nigel H., Raj, Kavita, Schwarer, Anthony P., Fong, Chun Yew, Grigg, Andrew P., Wei, Andrew H.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Haematological Malignancy ‐ Clinical
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048658/
https://ncbi.nlm.nih.gov/pubmed/32458446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16722
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados